



Cosmo appoints New CSO as current CSO retires

Dublin, Ireland – November 26, 2019 – Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that Luigi Moro, its Chief Scientific Officer, is retiring and that Roberto Camerini MD will assume his responsibilities as of January 1, 2020.

Luigi Moro joined Cosmo in 1999 after a long career in drug development in Farmitalia Carlo Erba, Recordati and Poli Industria Chimica. He led the development of all approved Cosmo products to date, namely Lialda, Uceris, Eleview and Aemcolo; and he also led the development of all Cassiopea products to date. Mr. Moro will continue making his services available as a consultant to Cosmo and will continue being the CSO of Cassiopea.

Roberto Camerini MD joined Cosmo in December 2018. He was formerly Director of Pre-Clinical and Clinical Research and Development at Alfa Wassermann S.p.A. from 2015 to 2018, and Head of Corporate Clinical Research at Sigma Tau S.p.A. Previously he worked for Serono and Abbot.

Mauro Ajani, Executive Chairman of Cosmo said: *“I recruited Luigi when we were but a handful of people. His expertise contributed in an essential fashion to the transformation of Cosmo from a small contract drug manufacturer to a listed specialty pharma company and I will be forever thankful for that. It is great that he is willing to continue making his experience available to the Company. We believe we have found in Roberto Camerini the right successor to lead our product development”*.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in colonoscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Financial calendar / next events

Full-year results 2019 reporting
Annual General Meeting

April 3, 2020
May 28, 2020

Contact:

Niall Donnelly, Chief Financial Officer & Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

ndonnelly@cosmopharma.com

Disclaimer

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.